



FOR RELEASE  
January 25, 2011

**Contacts:** Rob Stewart  
Investor Relations  
Tel (949) 480-8300  
Fax (949) 480-8301

**Media Contact:** Adam Handelsman  
Managing Director  
Lippert/Heilshorn & Associates  
(212) 201-6622  
[ahandelsman@lhai.com](mailto:ahandelsman@lhai.com)

### ACACIA EXPANDS MANAGEMENT TEAM

Newport Beach, CA. – (BUSINESS WIRE) January 25, 2011 - Acacia Research Corporation (Nasdaq:ACTG) announced today that Robert Rauker has joined the Acacia Research Group LLC as Vice President.

Mr. Rauker began his intellectual property career as an associate attorney with Oppenheimer, Wolff & Donnelly LLP, in Minneapolis from 1995-1998, was patent counsel at Boston Scientific Corporation/Scimed Life Systems from 1998-2000, was Chief IP Counsel, Endoscopy at Boston Scientific Corporation from 2000-2004, and was Vice President, Global Chief IP and Licensing Counsel at Synthes, Inc., a \$3.5 billion orthopedic company, from 2004-2009. Most recently he was Of Counsel at Conrad O'Brien PC in Philadelphia serving leading medical device companies.

Mr. Rauker implemented the first-ever global IP and licensing department at Synthes and his department negotiated over 100 licensing agreements involving key new technologies and managed and won several patent infringement suits involving major competitors.

As Chief Intellectual Property Counsel for the \$1 billion Endoscopy division of Boston Scientific, he managed and directed all strategic aspects of intellectual property including licensing and M&A activities.

Mr. Rauker holds both a B.S., Engineering and M.B.A. from the University of Massachusetts and a J.D. from the University of New Hampshire School of Law.

Acacia's CEO, Paul Ryan, commented, "Mr. Rauker is a great addition to Acacia's management team as we continue to build the country's leading patent licensing company. His extensive experience in intellectual property and licensing will be very valuable as we continue to expand our medical technology licensing business."

## **ABOUT ACACIA RESEARCH CORPORATION**

Acacia Research's subsidiaries partner with inventors and patent owners, license the patents to corporate users, and share the revenue. Acacia Research's subsidiaries control 170 patent portfolios, covering technologies used in a wide variety of industries.

Information about Acacia Research is available at [www.acaciatechnologies.com](http://www.acaciatechnologies.com) and [www.acaciaresearch.com](http://www.acaciaresearch.com).

### **Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995**

*This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements, including those related to Mr. Rauker's employment and impact therefrom, are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including Mr. Rauker's continued employment and his ability to expand our business in the medical technology area, the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.*